Results 11 to 20 of about 455,115 (204)
Haematologica, 2016 Response criteria for multiple myeloma are based upon changes in monoclonal protein levels quantified using serum and/or urine protein electrophoresis.
Thomas Dejoie +4 more
doaj +2 more sources
Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients [PDF]
Biomedicines, 2022 Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen +3 more
doaj +2 more sources
Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. [PDF]
PLoS ONE, 2009 The amyloidoses are protein misfolding diseases characterized by the deposition of amyloid that leads to cell death and tissue degeneration. In immunoglobulin light chain amyloidosis (AL), each patient has a unique monoclonal immunoglobulin light chain ...
Tanya L Poshusta +5 more
doaj +2 more sources
Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis
Haematologica, 2016 Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease.
Katherine M. Bever +8 more
doaj +2 more sources
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis [PDF]
Blood Cancer Journal, 2023 Rajshekhar Chakraborty +5 more
doaj +2 more sources
IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis
Hemato, 2022 Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek +3 more
doaj +1 more source
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment
American journal of hematology/oncology, 2022 Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar +1 more source
International Journal of Medicine and Health Development, 2023 Background: Abnormal plasma cells in multiple myeloma produce excessive amounts of immunoglobulins and free light chains, of which certain patterns predict patient survival.
Ifeyinwa D Nnakenyi +6 more
doaj +1 more source
Amyloidogenicity of Immunoglobulin Light Chains [PDF]
Biophysical Journal, 2015 Systemic light chain amyloidosis (AL) is a rare protein aggregation disease. It usually strikes in the wake of myeloma, which affects plasma cells in the adaptive immune system. During plasma cell development, the immunoglobulin light chain (LC) genes undergo several rearrangements that leave each clone with a unique protein sequence.
Kathrin Andrich +4 more
openaire +2 more sources
Immunoglobulin light chain amyloidosis
memo - Magazine of European Medical Oncology, 2021 Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains.
H. Agis, M. Krauth
semanticscholar +1 more source